These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30343173)

  • 1. Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.
    Edwards P; Davidson M; Calamai V; Cunningham D; Starling N
    Cancer Treat Rev; 2018 Dec; 71():32-38. PubMed ID: 30343173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
    Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
    Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.
    Davidson M; Chau I
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Petrelli F; Tomasello G; Barni S
    Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oesophagogastric junction adenocarcinoma: which therapeutic approach?
    Mariette C; Piessen G; Briez N; Gronnier C; Triboulet JP
    Lancet Oncol; 2011 Mar; 12(3):296-305. PubMed ID: 21109491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
    Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
    World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for oesophagogastric cancer.
    Davidson M; Chau I
    Expert Opin Biol Ther; 2016 Oct; 16(10):1197-207. PubMed ID: 27409159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategies around PD-L1 testing in France].
    Penault-Llorca F
    Ann Pathol; 2017 Feb; 37(1):3-4. PubMed ID: 28108043
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
    Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
    Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
    Al-Batran SE; Lorenzen S
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
    De Mello RA; Lordick F; Muro K; Janjigian YY
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progression of immunotherapy in gastric cancer].
    Wei X; Xu R
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of Gastric Cancer.
    Strand MS; Lockhart AC; Fields RC
    Surg Clin North Am; 2017 Apr; 97(2):345-370. PubMed ID: 28325191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
    Singh P; Toom S; Huang Y
    J Hematol Oncol; 2017 May; 10(1):105. PubMed ID: 28494772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
    Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodality therapy of local regional esophageal cancer.
    Kelsen DP
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S6-10. PubMed ID: 16399422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials.
    Naher SK; Mercieca-Bebber R; Siu D; Stockler MR; Kiely BE; Grimison P
    Curr Med Res Opin; 2024 Aug; 40(8):1357-1367. PubMed ID: 38961804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
    Fong CY; Chau I
    Pharmacogenomics; 2021 Jul; 22(11):703-726. PubMed ID: 34120461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.